***Background.*** Ceftolozane/tazobactam (TOL/TAZ) is a novel antibacterial with activity against *P. aeruginosa* (PSA) and other common Gram-negative pathogens (GN). TOL/TAZ is currently under clinical development for the treatment of nosocomial pneumonia, complicated intra-abdominal infections and complicated UTIs. The in vitro activity of TOL/TAZ was tested against GN in patients hospitalized with pneumonia in USA hospitals.

***Methods.*** 1458 isolates were consecutively collected in 29 USA hospitals from patients with pneumonia in 2013. Susceptibility (S) testing was performed by CLSI broth microdilution methods (TOL/TAZ at a fixed 4 µg/mL of TAZ).

***Results.*** PSA was the most common pathogen (39.8%) and TOL/TAZ was the most active β-lactam tested against PSA (97.6% inhibited at ≤8 µg/mL). PSA exhibited moderate S to meropenem (MEM, 78.1%), ceftazidime (CAZ; 83.0%), cefepime (FEP, 81.2%), piperacillin/TAZ (PIP/TAZ; 75.7%), levofloxacin (LVX; 72.6%), and gentamicin (GEN; 86.0%). TOL/TAZ exhibited activity against CAZ-non-S, MER-non-S PSA, and MDR PSA isolates (Figure). TOL/TAZ was active against *K. pneumoniae* (KPN; MIC~50/90~, 0.5/ \> 32 µg/mL) but activity was lower (MIC~50/90~, 32/ \> 32 µg/mL) against ESBL-phenotype KPN (31.2%); similar to all β-lactams \[including MER (32.2% S)\] and LEV (18.6% S) and GEN (57.6% S). TOL/TAZ inhibited 84.2% of MEM-S-ESBL-KPN at ≤8 µg/mL*.* TOL/TAZ was active against *E. coli* (MIC~90~, 0.5 µg/mL), including ESBL-phenotype isolates (MIC~90~, 1 µg/mL). TOL/TAZ inhibited 93.4 and 96.2% *Enterobacter* spp. (ESP) and *Serratia* spp., respectively, at ≤8 µg/mL, and demonstrated activity against CAZ-non-S ESP (70.3% inhibited at ≤8 µg/mL). TOL/TAZ was active against *P. mirabilis* (MIC~90~, 0.5 µg/mL), *Citrobacter* spp. (MIC~90~, 4 µg/mL) and indole (+) *Proteae* (MIC~90~, 1 µg/mL). All β-lactams had limited activity against *Acinetobacter* spp.

***Conclusion.*** In GN isolates from hospitalized patients with pneumoniae in USA hospitals, TOL/TAZ demonstrated greater in vitro activity than currently available cephalosporins, carbapenems, and P/T when tested against PSA, including MDR strains. Additionally, TOL/TAZ demonstrated greater activity than currently available cephalosporins and PIP/TAZ against Enterobacteriaceae from pneumonia specimens.
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